Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod in Japanese adults with moderately to severely active ulcerative colitis
jRCT2080224654Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ozanimod in autoimmune colitis (3 arms), sponsored by Bristol Myers Squibb. Started Apr 2019; status: completed.
02
Drugs
ozanimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080224654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224654.